Catalog Home Page

In Vitro Validation of Phosphorodiamidate Morpholino Oligomers

Aung-Htut, M.T., McIntosh, C.S., West, K.A., Fletcher, S. and Wilton, S.D. (2019) In Vitro Validation of Phosphorodiamidate Morpholino Oligomers. Molecules, 24 (16). p. 2922.

[img]
Preview
PDF - Published Version
Download (1MB) | Preview
Free to read: https://doi.org/10.3390/molecules24162922
*No subscription required

Abstract

One of the crucial aspects of screening antisense oligonucleotides destined for therapeutic application is confidence that the antisense oligomer is delivered efficiently into cultured cells. Efficient delivery is particularly vital for antisense phosphorodiamidate morpholino oligomers, which have a neutral backbone, and are known to show poor gymnotic uptake. Here, we report several methods to deliver these oligomers into cultured cells. Although 4D-NucleofectorTM or Neon. electroporation systems provide efficient delivery and use lower amounts of phosphorodiamidate morpholino oligomer, both systems are costly. We show that some readily available transfection reagents can be used to deliver phosphorodiamidate morpholino oligomers as efficiently as the electroporation systems. Among the transfection reagents tested, we recommend Lipofectamine 3000TM for delivering phosphorodiamidate morpholino oligomers into fibroblasts and Lipofectamine 3000TM or Lipofectamine 2000. for myoblasts/myotubes. We also provide optimal programs for nucleofection into various cell lines using the P3 Primary Cell 4D-NucleofectorTM X Kit (Lonza), as well as antisense oligomers that redirect expression of ubiquitously expressed genes that may be used as positive treatments for human and murine cell transfections.

Item Type: Journal Article
Murdoch Affiliation: Centre for Molecular Medicine and Innovative Therapeutics (CMMIT)
Publisher: MDPI
Copyright: © 2019 MDPI AG. All rights reserved.
United Nations SDGs: Goal 3: Good Health and Well-Being
URI: http://researchrepository.murdoch.edu.au/id/eprint/50463
Item Control Page Item Control Page

Downloads

Downloads per month over past year